Patent Application
20080267930
The present invention relates to the reprogramming of a differentiated cell or cell nucleus and uses thereof of the reprogrammed cell and/or cell nucleus. In particular, the invention describes methods of reprogramming a differentiated cell to produce an embryonic stem cell-like cell.
Embryonic stem cells are pluripotent stem cells which are capable of generating any other cell type in the organism from which they are derived. Pluripotent cells have the ability to develop into all three embryonic tissue layers which in turn form all the cells of every body organ and is used to describe stem cells that can form any and all cells and tissues in the body. This differs subtly from totipotent cells which have the capacity to specialize into extraembryonic membranes and tissues, the embryo, and all postembryonic tissues and organs.
Differentiated cells are cells which make up the somatic tissues within an organism and are, under normal in vivo circumstances, generally considered to be restricted in their developmental potential. Differentiated cells may be either terminally differentiated, that is, they are developmentally arrested as a particular cell type (for example, neurons, myocytes and osteocytes), or they may retain the potential to give rise to a limited number of other cell types within a specific lineage (for example, a myeloid progenitor cell which can produce a variety of immune cells including basophils, eosinophils, and neutrophils).
Mammalian, and in particular human, embryonic stem cells offer the potential for the treatment and/or prevention of many human diseases or conditions. In particular, embryonic stem cells offer a means to generate a large range of human cell types, such cells being of great therapeutic value. However, currently in most developed countries there are ethical and practical issues surrounding the obtaining and use of mammalian, and in particular human, embryonic stem cells.
Embryonic stem cells are normally derived from a pluripotent population of cells in an embryo known as the inner cell mass (ICM) which is the population of cells from which an entire organism is derived. The ICM arises early in development, typically three to five days after fertilisation depending on the species in question. Using cloning procedures it is possible to produce embryos from any individual of a given species. Typically, in current cloning procedures the nucleus of a mammalian differentiated cell is transferred into an enucleated mammalian oocyte, usually from the same species in a process known as nuclear transfer (Campbell et al., 2005, Reprod Dom Anim 40:256-268).
Nuclear transfer is known to be difficult to perform and to have a low frequency of success (Campbell et al., 2005, Reprod Dom Anim 40:256-268). When successful, the transferred nuclear DNA is reprogrammed by the recipient oocyte and the oocyte can then be stimulated, by mimicking the effect of fertilisation, to form an embryo.
Usually the oocyte is stimulated into mitosis and either at the morula or blastocyst stage is implanted into the uterus of a ‘foster’ mother. This procedure has a very low success rate and produces very few viable embryos. In those cases where an embryo forms, the ICM may be isolated to provide embryonic stem cells which can be used in other applications.
When this process is applied to human, or mammalian, embryos it is referred to as therapeutic cloning, which has both practical and ethical considerations. In practical terms, obtaining embryonic stem cells requires the donation of eggs from a female, which is limited in practice as mammalian eggs are expensive to recover and very few eggs can be obtained from one female. In ethical terms and particularly in relation to humans, there are widespread objections to the generation of an embryo as an intermediate in another process, for example in therapeutic cloning where the embryo produced serves only as a donor of embryonic stem cells.
Hence, there is a need to develop pluripotent, embryonic stem cell-like cells which can be used in therapeutic procedures but that can be obtained without the cloning procedure, and in particular without using mammalian oocytes to produce embryos simply to provide embryonic stem cells.
The nuclei of differentiated cells have previously been successfully reprogrammed towards a pluripotent state by the production of viable fertile animals from cloning experiments with differentiated cells (Wilmut et al (1997) Nature 385:810-813; Polejaeva et al (2000) Nature 407:86-90). These procedures have very low efficiencies and success rates. In these procedures the differentiated nucleus was reprogrammed to pluripotency by nuclear transfer into an enucleated mammalian oocyte and exposure to factors within the mammalian oocyte which reactivated genes in the cell nucleus that conferred pluripotency to the cell via the creation of an embryo. In these cases all the manipulations were performed using material from the same species as the cell of interest.
Pluripotency in a cell may be identified by looking for the expression of a number of marker genes. In a human these genes include POU5Fi (encoding the transcription factor Oct-4), NANOG, Rex-1, Sox-2 and Tert (Ginis et al., 2004 Dev Biol 269:Pages 360-380). The skilled man will understand from the context in which POU5 (Oct-4) and NANOG, or any other genes or proteins are referred to whether it is the gene or the gene product which is being discussed.
Oct-4 is a transcription factor normally found and expressed in pluripotent cells, including embryonic stem cells, but it is not expressed in normal differentiated cells. The activation of Oct-4 is consistent with the cells being reprogrammed towards a state resembling pluripotency. Experimental elimination of Oct-4 results in the complete absence of an ICM in embryos, and the loss of an undifferentiated phenotype in embryonic stem cells which go on to differentiate into primitive ectoderm (Nichols et al (1998) Cell. 95:379-391).
Nanog is another transcription factor also found in pluripotent cells. In the absence of nanog expression embryonic stem cells lose their pluripotency (Chambers (2004) Cloning Stem Cells 6:386-391).
There is a need for methods of producing embryonic stem cells or cells that resemble embryonic stem cells (so-called embryonic-stem cell like cells) without the creation of whole embryos in order to overcome both the practical and ethical considerations of the stem cell field. Hence, the present invention provides methods of re-directing the developmental potential of differentiated cells and/or their nuclei e.g. differentiated cells from mammals, to a more pluripotent state resembling that of an embryonic stem cell in a process known as reprogramming.
In a first aspect of the invention there is provided a method of producing a reprogrammed cell or reprogrammed cell nucleus, comprising exposing a differentiated cell, or the nucleus of a differentiated cell to a cell or cell extract thereof derived from an oocyte, egg, ovary or early embryo of a cold blooded vertebrate, wherein the cold blooded vertebrate has one or more of the following properties:
Preferably the oocyte, egg, ovary or early embryo cell or cell from which the cell extract is derived, expresses both Oct-4 in a highly conserved form and nanog.
Alternatively the method can be described as a method of reprogramming a differentiated cell to express nanog and/or express Oct-4 and/or be pluripotent comprising exposing a differentiated cell to an oocyte, egg, ovary or early embryo, or an extract thereof, from a cold blooded vertebrate, wherein the cold blooded vertebrate has one or more of the following properties:
(i) a primitive vertebrate body plan including laterally projecting ribs and/or spinal projections and/or pelvic appendages in fish extending from a posteriorly located pelvic bone.
(ii) germ cells which do not contain germ plasm; and/or
(iii) the oocyte, egg, ovary or early embryo cell or cell from which the cell extract is derived, expresses Oct-4 in a highly conserved form and/or nanog in a highly conserved form.
Preferably the oocyte, egg, ovary or early embryo cell or cell from which the cell extract is derived, expresses both Oct-4 in a highly conserved form and nanog.
Further alternatively the method can be described as the present invention provides a method of producing an embryonic stem cell-like cell, or a method of producing a reprogrammed cell nucleus, comprising contacting a differentiated cell, or the nucleus of a differentiated cell, with an oocyte, egg, ovary or early embryo, or an extract thereof, from a cold blooded vertebrate, wherein the cold blooded vertebrate has one or more of the following properties:
A reprogrammed cell is a cell which has had its normal differentiated function removed or altered. A reprogrammed cell nucleus is a nucleus whose normal differentiated function has been removed or altered.
A differentiated cell is a cell which has developed into a particular cell type with a specified function e.g. a nerve cell, or muscle cell. These cells under normal circumstances cannot generally develop to other cell types. In the context of this invention a re-differentiated cell is a cell which has been of one particular cell type and has been manipulated using the methods of the invention to form a stem cell and subsequently converted into a differentiated cell again. The re-differentiated cell may be of the same type or a different type of cell as in its original differentiation.
Whether an organism has a primitive vertebrate body plan can be determined by considering one or both of two specific criteria pertaining to their skeletal structures. The first criterion relates to the rib structure and the second criterion relates to the pelvic bone. Primitive fish and primitive amphibians have similar skeletal structures, which is in marked contrast to the skeletal structure of organisms with so called “derived” skeletons (anuran (frog) skeletons; teleost skeletons).
An organism with a primitive vertebrate body plan, such as a lungfish or a salamander, has ribs which radiate laterally from a backbone. This is the primitive condition of the vertebrate skeleton which gave rise to the rib cage in mammals. By way of contrast in an organism, such as a teleost fish, which has a derived body plan, the ribs radiate dorso-ventrally, not laterally. This difference allows fish with a primitive vertebrate body plan to be distinguished from those without.
As an alternative to considering the ribs, an organism with a primitive vertebrate body plan can also be identified by considering the pelvic bone. In primitive fish pelvic appendages extend from the pelvic bone in the posterior region of the skeleton. In the skeletons of teleosts the pelvic bone is found in a much anteriorised position near or adjacent to or even fusing with the pectoral girdle, positioning the pelvic fins at about the half-way point of the fish's body or even anterior of that point, near the head. The primitive amphibian skeleton exemplified by the salamander (axolotl) retains a pelvic bone attached to the posterior region of the skeleton. Frogs in contrast have a highly derived and expanded pelvic girdle. In addition frogs have a much reduced number of vertebrae anterior to the pelvic girdle.
The lungfish skeleton is shown from a dorsal view (from the back). Importantly, the teleost shows a side view, illustrating that the spinal projections/ribs radiate dorso-ventrally, not laterally. The amphibians are both dorsal views. In the fish the small arrows point to bones/ribs which project laterally from the backbone in the lungfish. This is the primitive condition of the vertebrate skeleton which gave rise to the rib cage. Note that the teleost ribs project ventrally, not laterally. This is a teleost innovation. The dorsal and ventral spinal projections which support the fins are also a teleost innovation. Primitive fish retain four limbs, which evolved into the four limbs of tetrapods, four-limbed land dwelling animals. Importantly, the large arrow points to the pelvic bone in the primitive fish and primitive amphibian. This is a feature that defines primitive fish, as it is lost in teleosts. The primitive vertebrate body plan is discussed in more detail in Johnson et al (2003) Evolution and Development 5:4, 414-431.
Sturgeon, turtle, lungfish, and mammals all share a similar embryology, as defined by gastrulation movements.
Therefore, the primitive vertebrate body plan can be identified, for example on x-rays, by the lateral and no dorsoventral projection of ribs and/or spinal projections. An alternative skeletal identification is the pelvic bone in fish.
Germ Cells without Germplasm
In females a germ cell refers to an oocyte or a precursor cell to an oocyte.
An oocyte defines the female germ cell when in the ovary, and an egg defines the female germ cell after ovulation.
Germ plasm is a region of cytoplasm found in the egg, oocyte or embryo of some organisms which contains determinants that will give rise to the germ cell lineage. In animals without a germ plasm these same molecules are distributed throughout the egg cytoplasm, and possibly the GV (germinal vesicle) as well. These molecules, such as the products of the nanos, vasa and dazl genes, are typically RNA binding proteins, or the messenger RNAs that encode these, that are likely to be involved in the pluripotency reprogramming process since they are found in embryonic stem cells. It is considered that in organisms with a germ plasm these molecules are localized, and therefore probably in low abundance and relatively unavailable in oocytes, eggs, ovaries or early embryos, or extracts thereof, thus making organisms with a germ plasm unsuitable for reprogramming differentiated cells.
Preferably, in relation to the invention, a cold blooded vertebrate with a primitive vertebrate body plan also has oocytes/eggs (germ cells) which do not contain germ plasm. The presence or absence of germ plasm may explain how certain organisms developed. Indeed by looking at the body plan of an organism it is possible to predict whether the oocytes/eggs in that organism will have a germ plasm. The hind limbs in particular, which define the posterior extreme of the body trunk, are crucial. In the absence of germ plasm the germ cells are derived from posterior-lateral mesoderm, at about the vertebral position defined by the pelvic bone and they are formed in response to extracellular signals exclusive to this posterior region of the embryo. These cells later develop into oocytes. In the presence of germ plasm the germ cells develop in a more anterior position and the resulting organism has a relatively anterior adult morphology. The oocytes, eggs, ovaries and early embryos of organisms with a germ plasm are less efficient at cell and nucleus reprogramming when compared to those without a germ plasm.
Organisms which display a primitive vertebrate body plan are understood not to have germ plasm in their germ cells. The retention of the primitive vertebrate body plan is believed to be a consequence of the absence of a germ plasm.
For the purposes of identifying animals whose oocytes/eggs contain germ plasm, the hindlimbs, defining the posterior extreme of the body trunk are crucial. In the absence of germ plasm germ cells are derived from posterior-lateral mesoderm, at about the vertebral position defined by the pelvic bone. Animals whose eggs contain germ plasm do not require the extracellular posterior signals required to produce germ cells as the cells are specified by material supplied by the egg, not from extracellular signals. Therefore, in most animals with germ plasm, such as frogs and teleost fish, the animals have a relatively anterior adult morphology. The oocytes and eggs of these animals are not as useful for reprogramming.
It has been shown that the absence of germ plasm in mammals, once considered to be a mammalian innovation, has been conserved through a specific lineage of species that retain primitive embryological characteristics, which as a consequence result in the retention of a primitive vertebrate body plan in this lineage of animals. In the embryos of mammals and cold-blooded vertebrate species whose embryos retain primitive characteristics, and retain a primitive adult vertebrate morphology the stem cells that give rise to the germ line (sperm and eggs), known as PGCs, are derived from pluripotent precursors that arise early in development. Whereas in most experimental, non-mammalian, organisms such as Xenopus or zebrafish (a teleost) the PGCs are formed by an entirely different mechanism than in mammals, and pluripotent precursors equivalent to those of mammals are never formed. In Xenopus and zebrafish the germ cells are segregated very early from somatic cells by the unequal distribution of germ plasm, containing germ cell determinants. The cells that inherit the germ plasm then become the PGCs, and do not give rise to somatic cells.
It is now believed that the mechanism to produce PGCs in mammals is present in some lower animals, but only in those species that meet specific criteria. These species can be identified on the basis of their body plan. Species that meet the criteria, such as axolotl, have PGC development similar to that in mammals, and a similar complement of genes that govern germ cell development, such as the genes encoding Oct-4, and nanog and are therefore able to reprogram differentiated cells, and in particular mammalian differentiated cells. It is therefore possible to accurately predict that the oocytes of certain species which meet the aforementioned criteria will have reprogramming potential equivalent to that of axolotls. Species that do not meet these criteria will not have the same complement of conserved pluripotency genes and thus will not have equivalent reprogramming capability. The species meeting the criteria have a primitive vertebrate body plan which is believed to be a consequence of the absence of a germ plasm. Importantly, since Oct-4 and nanog are required to produce PGCs in the absence of germ plasm, the retention of Oct-4 and nanog is believed to be a consequence of having no germ plasm.
Adults are a product of their embryology. Therefore, the adult body plan is conserved because the embryology is conserved. What constrains the embryology, preventing the major changes seen in frogs and teleosts, is the mechanism for producing germ cells. In animals without germ plasm the PGCs have a more tenuous existence, they can be wiped out if the signals required for their production are altered, as would happen with a major change in embryological cell movements. If germ plasm is present, the PGCs are refractory to these changes in signals, because they form no matter what. Thus, constraints on the embryology are lifted, the cell movements of embryology change, and this is why animals with germ plasm are capable of having an altered morphology from the primitive body plan. Without germ plasm this couldn't happen. Sturgeon, turtle, lungfish, and mammals all share a similar embryology, as defined by gastrulation movements.
Expression of Oct-4 and/or Nanog
Preferably a cold blooded vertebrate retaining a primitive vertebrate body plan also has oocyte, egg, ovary or early embryo cells which express Oct-4 and/or nanog.
Oct-4 and/or Nanog expression may be determined by assaying for mRNA encoding the protein or for the protein product itself. Examples of methods of assays to do this include RT-PCR method to assay mRNA described in Makin et al. technique 2 p 295-301 (1990) or antibody assays for the protein product.
In order for Oct-4 and/or nanog in the oocyte, egg, ovary or early embryo cells to be considered highly conserved it must share at least 69% amino acid identity with the DNA binding domains (DBD) of the human transcription factor Oct-4 or the human nanog protein, respectively. In the case of the axolotl Oct-4 protein, AxOct-4, 73% of the amino acids are identical to the mouse Oct-4 DBD, and 75% are identical to the human Oct-4 DBD. The closest proteins from zebrafish and Xenopus, encoded by the genes ZPOU-2 and XLPOU91, and which do not confer the ability to reprogram differentiated cells respectively, are 63% identical, less than the required 69% identity. The identity and activity of the functionally equivalent Oct-4 genes can be tested using standard methods known to the skilled man such as those described in the example.
Preferably the amino acid identity referred to between the human Oct-4 DBD and that of a cold blooded vertebrate allows for conservative changes in the amino acids which do not alter the polarity or charge of the amino acid residue. Examples of conservative changes are well known to those skilled in the art, and include, for example, substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for lysine. Preferably, when determining the amino acid identity between two protein sequences conservative amino acid changes are considered to be identical amino acids. Therefore, a conservative amino acid change in amino acid sequence will not affect the percentage amino acid identity between to two sequences.
To further support the understanding discussed above, the gene encoding Oct-4 in various species was compared, and those sharing the identified morphological features were shown to have more closely related Oct-4 encoding genes than species lacking the morphological features. In these experiments the Oct-4 encoding genes were isolated from newt (Notopthalmus viridens), the gulf sturgeon (Asciperser oxyrhynchus), the African lungfish (Protopterus annectans) and the Red Eared Slider (a turtle, T. scripta) all of which fulfil the criteria described for primitive morphology. In
The Oct-4 gene (Axoct-4) in the axolotl (the salamander species Ambystoma mexicanum) is more highly related to the mammalian Oct-4 gene than any other gene in the database, including several genes from Xenopus that are related to Oct-4, and can rescue ES cells, in some cases, such as XLPOU91, better than the axolotl Oct-4 gene (Morrison and Brickman, 2006). (
In mammals, Oct-4 is required to produce PGCs. This is not the case in Xenopus, meaning that any Oct-4 equivalent genes are not a true orthologs of the mammal Oct-4. The expression pattern and homology of mechanism of Oct-4 in axolotl now suggest Oct-4 is required to produce PGCs. This observation may contribute to why axolotl oocytes have a greater capacity to reprogram mammalian differentiated cells to pluripotency than Xenopus cells, the axolotl oocytes behaving more like mammalian oocytes in reprogramming capacity. Also, since the absence of germ plasm also makes these oocyte/eggs more similar to mammals, this is likely to also be involved in the superior reprogramming capacity of axolotls compared to Xenopus. The absence of a germ plasm may allow other factors such as Nanos, vasa and dazl which are all RNA binding proteins associated with germ plasm to be more accessible for reprogramming.
Having demonstrated that axolotls, which have an Oct-4 gene more closely related to mammalian Oct-4 genes than the Oct-4 gene of frogs, it is understood that other organisms with an Oct-4 gene more closely related to the mammalian Oct-4 gene will also be able to reprogram mammalian differentiated cells. Also, the expression pattern of Axoct-4 is equivalent to that of early mammalian embryos. Thus sturgeon and lungfish, other salamanders, and the “primitive fish” will all have a reprogramming capacity equivalent to axolotl, and far greater than that of Xenopus, other frogs, or teleosts.
Preferably the reprogrammed cell is an embryonic stem cell-like cell.
The term “embryonic stem cell-like cell” is used herein to refer to a differentiated cell that has been reprogrammed to exhibit a property of an embryonic stem cell, or a cell containing a reprogrammed differentiated nucleus which exhibits a property of an embryonic stem cell. An embryonic stem cell-like cell may include one or more of, but not limited to, the following properties: proliferation without transformation; continuous proliferation; self renewal and capacity to generate a wide range of tissues; the ability to differentiate into either the same or a different cell type than the original differentiated cell (pluripotency); when compared with these same parameters in the cell prior to being de-differentiated or reprogrammed.
Preferably, the reprogrammed cell, and/or the reprogrammed cell nucleus, expresses Oct-4. Alternatively the reprogrammed cell, or the reprogrammed cell nucleus, expresses only nanog. The reprogrammed cell, or the reprogrammed cell nucleus may also be pluripotent.
Conveniently the reprogrammed cell, and/or the reprogrammed cell nucleus produced according to any method of the invention may express both Oct-4 and nanog and/or other markers of pluripotency. Other markers of pluripotency include Sox-2, Rex-1, and TERT.
Whether a cell is pluripotent can be identified by the presence of pluripotent properties, that is that the cell can be stimulated to differentiate into almost any cell type in the organism from which it is derived. Differentiation of pluripotent cells can be induced by exposure of the pluripotent cell to a progenitor medium and/or certain growth factors Lanza, 2004. Handbook of Stem Cells: Embryonic/Adult and Foetal Stem Cells.
Preferably the Oct-4 and/or the nanog in the cold-blooded vertebrate oocyte, egg, ovary or early embryo cell or cell extract are highly conserved in comparison to the human form, by this we mean the Oct-4 in the cold-blooded vertebrate has at least 69% amino acid identity in the DNA binding domain with the human transcription factor Oct-4. Preferably with the nanog gene this would be at least 69% and most preferably 75% identity with the homeo domain shared with the human nanog protein,
Advantageously the Oct-4 and/or the nanog in the cold blooded vertebrate oocyte, egg, ovary or early embryo cells has at least 69% amino acid identity with the DNA binding domains (DBD) of the human transcription factor Oct-4 or the human nanog protein, respectively.
Amino acid identity can be measured using ClustalW (Thompson et al. (1994) Nucl. Acids. Res., 22 p 4673-4680, or any alternative amino acid sequence comparison tool. The clustalW method can be used with the following parameters:
Pairwise alignment parameters—method:accurate
Matrix: PAM, Gap open penalty 10.00, Gap extension penalty: 0.10;
Multiple alignment parameters—Matrix: PAM, Gap open penalty: 10.00,
% identity for delay: 30; Penalize end gaps: on. Gap separation distance 0, Negative matrix: no, Gap extension penalty: 0.20, Residue—specific gap penalties: on, Hydrophilic gap penalties: on, Hydrophilic residues: GPSNDQEKR. Sequence identity at a particular residue is intended to include identical residues which have simply been derivatized.
Alternative parameters may also be suitable.
Nucleotide sequence identity can also be measured using ClustalW (Thompson et al (1994)) using the following parameters:
Pairwise alignment parameters—Method: accurate,
Matrix: IUB, Gap open penalty: 15.00, Gap extension penalty: 6.66;
Multiple alignment parameters—Matrix: IUB, Gap open penalty: 15.00, % identity for delay: 30, Negative matrix: no, Gap extension penalty: 6.66, DNA transitions weighting: 0.5.
Alternative parameters may also be suitable.
Preferably, any nucleotide sequence encoding a conserved Oct-4 and/or nanog has more than 69% e.g. 75%, 80%, 90% or 95% identity to the human Oct-4 and/or nanog sequences (according to the test described above) or a sequence which hybridizes to human Oct-4 and/or nanog sequences under wash conditions of 0.1×SSC, 65° C. (wherein SCC=0.15 M NaCl, 0.015M sodium citrate, pH 7.2) which encodes a functionally equivalent protein to human Oct-4 and/or nanog.
Polypeptides of the invention include both full-length and fragments. Such polypeptides may be prepared by any conventional means.
Functionally equivalent proteins or protein fragments refer to proteins and/or fragments having at least 69% sequence identity and retaining the same function as human Oct-4 and/or nanog. Such function can be tested by any of the methods described herein.
“Nucleic acid molecules” according to the invention include single and double stranded DNA, RNA, cDNA. Derivatives of nucleotide sequences capable of encoding functionally-equivalent polypeptides may be obtained using any conventional method well known in the art.
The group of organisms predicted on the basis of body plan to lack a conserved Oct-4 gene, including all frogs, all teleost fish, all birds and the majority of reptiles is far larger than the group that retain a primitive body plan and that retain a conserved Oct-4 gene (including urodele amphibians) and a gene encoding an ortholog of nanog. Therefore only the oocytes, ovaries, eggs and early embryos, or extracts thereof, of a very small number of species are suitable for use in the present invention. The following lineages retain a conserved vertebrate body plan:
Salamanders (axolotl or notopthalamus)
Hyperotreti (hagfish);
Hyperoartia (lamprey);
Chondrichthyes (sharks, rays, skates, chimeras);
Chondrostei (bichirs, sturgeons, paddlefish);
Semionotiformes (gars);
Amiiformes (bowfins)
Dipnoi (lungfish); and
Coelacanthimorpha (coelacanths).
Hence it is preferred that the cold blooded vertebrate is selected from the group comprising amphibians, reptiles and fish.
Preferably the cold blooded vertebrate is selected from the group comprising salamanders, turtles, lizards, crocodilians, Hyperotreti (hagfish); Hyperoartia (lamprey); Chondrichthyes (sharks, rays, skates, chimeras); Chondrostei (bichirs, sturgeons, paddlefish etc); Semionotiformes (gars); Amiiformes (bowfins); Dipnoi (lungfish); and Coelacanthimorpha (coelacanths).
Most preferably the cold blooded vertebrate is selected from the group comprising salamanders, turtles, lungfish and sturgeon.
Conveniently the cold blooded vertebrate is a salamander, including axolotl and notopthalmus.
Alternatively to salamanders the cold blooded vertebrate is a sturgeon Scientific genus: Acipenser).
It is a particular advantage in that in a large proportion of the organisms mentioned it is relatively straightforward to obtain the oocytes, eggs, ovaries or early embryos cells or cell extracts thereof, and the material is abundant. Amphibians, and bony fish can have eggs several thousand times the volume of a mammalian egg and in quantities far exceeding mammalian egg tissue e.g. the sturgeon (from which caviar is obtained) can produce 15-25% of its bodyweight in egg cells. The recovered material can be stored and used as required.
By way of contrast, mammalian oocytes, eggs, ovarian material and/or early embryos are scarce and difficult to obtain, furthermore the material is very limited in amount.
The oocyte, egg, ovary or early embryo cells and cell extracts from Xenopus laevis or any other frog or any teleost fish are not suitable for use in any method of the invention. Frogs and teleost fish (both cold blooded vertebrae) are examples of amphibians and fish that do not retain a primitive body plan, their oocytes are known to contain germ plasm, and their Oct-4 protein is not highly conserved when compared to the human Oct-4 protein.
Preferably the oocyte, egg, or early embryo cell extract comprises material from the nucleus or germinal vesicle (GV) of the oocyte, egg, or early embryo cell.
The nucleus and GV contain specific transcription factors Oct-4 and Nanog.
The RNA encoding germ cell specific RNA binding proteins that are located in the germ plasm in frog sna teleosts Dazl, VASA, and Nanos are distributed uniformly in the cytoplasm (Johnson et al., 2001, 243:402-415; Dev. Biol.; Bachvarova et al., Dev. Dyn. 231, 871-880) and are capable of maintaining pluripotency or germ cell specification in germ cells with germ plasm but are not capable of reprogramming cells.
Exposure of the differentiated cell with the nucleus or germinal vesicle of the oocyte, egg, or early embryo of a cold blooded vertebrate according to the invention, or an extract thereof, may be achieved by injecting a permeabilised differentiated cell into the oocyte, egg, ovary cell or early embryo cell, or incubating a permeabilised differentiated cell with an extract of the oocyte, egg, ovary or early embryo.
Preferably the permeabilised differentiated cell allows factors in the oocyte, egg, ovary or embryo, or extract thereof, to pass into the cell and reprogram it, preferably mitochondria or the nucleus from the oocyte, egg, ovary cell or embryo cell cannot pass into the permeabilised cell and thus there is no exchange of genetic material. Permeabilisation of the differentiated cell can be achieved by any method well known in the art such as treating the cell with Triton-X-100, digitonin or saponin.
Preferably, after contact with the oocyte, egg, ovary or early embryo, or an extract thereof, of a cold blooded vertebrate according to the invention the reprogrammed cells are recovered by centrifugation onto a microscope slide or culture dish, using techniques well known in the art.
Preferably, in any method of the invention for reprogramming a differentiated cell nucleus, a differentiated cell nucleus may be contacted with an oocyte, egg, ovary or early embryo, by using well known nuclear transfer techniques which will be readily apparent to the skilled man (see refs discussed above). Such techniques include injection of the differentiated nucleus into an enucleated oocyte or egg; or fusion of a differentiated cell with an enucleated oocyte or egg.
Cell based work has the advantage that the reprogrammed cell is entirely contained within the cold-blooded vertebrate cell.
Alternatively, the differentiated cell nucleus may be incubated with an extract of oocyte, egg, ovary or early embryo.
Use of an extract has the advantage that it avoids the manipulation necessary to inject a differentiated cell or nuclei into an intact oocyte, egg or early embryos in order for factors in the oocyte, egg, ovary or early embryo to act on the differentiated cell or nuclei and cause its reprogramming. Using extracts also makes it easy to retrieve the material and allows thousands to millions of cells or nuclei to be reprogrammed at once. Furthermore, oocyte, egg, ovary and early embryo extracts of a cold blooded vertebrate according to the invention can be produced in large amounts and can be stored for use as dictated by convenience.
Preferably an extract of whole ovary is used. By using whole ovary extract there is no need to separate the cell components, which might be impossible with some species of cold blooded vertebrate. Alternatively, the raw material for the extract may be oocytes liberated from ovarian stroma by conventional techniques, for example 0.2% collagenase digestion.
A differentiated cell refers to a cell that has achieved a mature state of differentiation. Typically a differentiated cell is characterised by the expression of genes that encode differentiation-associated proteins in a given cell. For example, the expression of myelin proteins and the formation of myelin sheath in glial cells is a typical example of terminally differentiated glial cells. Differentiated cells are either unable to differentiate further or can only differentiate into specific cells in a particular cell lineage.
Preferably, the differentiated cell used in any method of the invention is a eukaryotic cell. Preferably the differentiated cell is obtained from a mammal. Most preferably the cell is human.
Preferably, in any method of the invention, the differentiated cell or nuclei thereof is exposed to the oocyte, egg, ovary or early embryo cell or cell extract thereof, at a temperature between about 5° C. and about 30° C., more preferably between about 5° C. and about 21° C. More preferably the differentiated cells or nuclei are contacted with the oocyte, egg, ovary or early embryo, or extract thereof, at a temperature consistent with the body temperature of the organism from which the oocyte, egg, ovary or early embryo cell or cell extract thereof, is derived. As the skilled person will appreciate, Cold blooded animals don't have a body temperature of their own per se, their bodies are the temperature of their environment. More preferably the contact temperature is about 18° C., or that of the environment in which the cold blooded vertebrate normally resides.
Preferably, a reprogrammed cell nucleus according to the invention expresses genes which are markers of pluripotency. Preferably the pluripotency marker genes include the gene encoding Oct-4 and nanog. The Oct-4 gene may be used as a marker if demethylation of the Oct-4 promoter occurs.
In a second aspect of the invention there is provided a reprogrammed cell produced according to the method of the first aspect of the invention. Preferably the reprogrammed cell is an embryonic stem cell-like cell.
In a third aspect of the invention there is provided a reprogrammed cell nucleus produced according to the method of the first aspect of invention.
Preferably, the reprogrammed cell nucleus may be subsequently used in standard known somatic cell nuclear transfer (SCNT) techniques. The efficiency of the SCNT techniques are enhanced by first reprogramming the differentiated cell nucleus according to the invention.
In a fourth aspect of the invention there is provided a method of producing a re-differentiated cell comprising:
(a) producing a reprogrammed cell as described in the first aspect of the invention; and
(b) re-differentiating the reprogrammed cell into a differentiated cell of the same type, or a different type, to the differentiated cell from which it is derived.
Preferably, the re-differentiation is effected using a progenitor medium. Once generated, the reprogrammed differentiated cell can be cultured in the presence of particular growth factors and other signalling molecules (progenitor medium) that induce their differentiation into particular cells types. Different progenitor media are required to produce different cell types.
The method of the invention allows pluripotent reprogrammed cells to be obtained from differentiated cells of an individual, these reprogrammed cells can then be differentiated into a cell type required to treat that patient.
In a fifth aspect of the invention there is provided a re-differentiated cell produced according to the method of the fourth aspect of the invention.
In a sixth aspect of the invention there is provided an isolated cell or cell extract derived from an oocyte, egg, ovary or early embryo of a cold blooded vertebrate, wherein the cold blooded vertebrate has one or more of the following properties:
(i) a primitive vertebrate body plan including laterally projecting ribs and/or spinal projections and/or pelvic appendages in fish extending from a posteriorly located pelvic bone;
(ii) germ cells which do not contain germ plasm; and/or
(iii) the oocyte, egg, ovary or early embryo cell or cell from which the cell extract is derived, expresses Oct-4 in a highly conserved form and/or nanog in a highly conserved form.
Preferably the oocyte, egg, ovary or early embryo cell or cell from which the cell extract is derived, expresses both Oct-4 in a highly conserved form and nanog.
Preferably the cell and/or cell extract comprises material from the nucleus or germinal vesicle (GV) of the oocyte, egg, or early embryo cell.
In a seventh aspect of the invention there is provided a pharmaceutical composition comprising the isolated cell or cell extract as defined in the sixth aspect of the invention and a pharmaceutically acceptable carrier, excipient or diluent.
Furthermore, there is provided a pharmaceutical composition comprising a reprogrammed cell as defined in the second aspect of the invention and/or a reprogrammed cell nucleus as defined in the third aspect of the invention or a re-differentiated cell as defined in the fifth aspect of the invention, and a pharmaceutically acceptable carrier, excipient or diluent. Suitable pharmaceutical carriers, excipients, and diluents and formulations are provided in the examples.
According to an eighth aspect of the invention there is provided method of treating a disease requiring the replacement or renewal of cells comprising administering to an animal an effective amount of isolated cell or cell extract as defined in the sixth aspect of the invention and/or an effective amount of reprogrammed cell as defined in the second aspect of the invention and/or a reprogrammed cell nucleus as defined in the third aspect of the invention or a re-differentiated cell as defined in the fifth aspect of the invention.
According to a ninth aspect of the invention there is provided an isolated cell or cell extract as defined in the sixth aspect of the invention and/or a reprogrammed cell as defined in the second aspect of the invention and/or a reprogrammed cell nucleus as defined in the third aspect of the invention and/or a re-differentiated cell as defined in the fifth aspect of the invention for use as a medicament.
According to a tenth aspect of the invention there is provided a use of the isolated cell or cell extract as defined in the sixth aspect of the invention and/or a reprogrammed cell as defined in the second aspect of the invention and/or a reprogrammed cell nucleus as defined in the third aspect of the invention and/or a re-differentiated cell as defined in the fifth aspect of the invention in the manufacture of a medicament for the treatment of a disease requiring the replacement or the renewal of cells
Different cell/tissue types are needed for subsequent use in different medical conditions.
For example, haematopoietic stem cells could be used to treat individuals suffering from leukaemia. Neural progenitor cells could be used to treat individuals suffering from neurodegenerative disorders, such as Alzheimer's or Parkinson's disease. Skin cells could be used for grafts in cases where an individual has suffered severe burns or scarring.
The use of stem cells for the generation of organs and tissues for transplantation provides a promising alternative therapy for diabetes, liver disease, heart disease and autoimmune disorders to name just a few. The main problems associated with transplantation are the lack of donors and the potential incompatibility of the transplanted tissue with the immune system of the recipient.
That is, the immunorejection of the transplanted tissue as the recipient views the transplant as foreign. Using the method of the invention embryonic stem cell-like cells can be derived from a patient in need of a transplant and then used to a produce tissue or an organ for transplantation into the same patient. This removes any problems of tissue incompatibility and immunorejection. Thus there is great therapeutic potential in being able to generate pluripotent embryonic stem cell-like cells, in particular where they are genetically identical to those of the patient.
Hence in the eighth, ninth and tenth aspects of the invention the disease is selected from the group comprising neurological disease (Parkinson's disease, Alzheimer's disease, spinal cord injury, stroke), skin alternation, burns, heart disease, diabetes, osteoarthritis and rheumatoid arthritis.
Preferably the disease is a neurological disease and conveniently the disease is selected from the group comprising Parkinson's disease, Alzheimer's disease, spinal cord injury, stroke.
In an eleventh aspect of the invention there is provided a kit for reprogramming a differentiated cell, or for reprogramming the nucleus of a differentiated cell, comprising a cell or cell extract thereof derived from an oocyte, egg, ovary or early embryo of a cold blooded vertebrate, wherein the cold blooded vertebrate has one or more of the following properties:
(i) a primitive vertebrate body plan including laterally projecting ribs and/or spinal projections and/or pelvic appendages in fish extending from a posteriorly located pelvic bone;
(ii) germ cells which do not contain germ plasm; and/or
(iii) the oocyte, egg, ovary or early embryo cell or cell from which the cell extract is derived, expresses Oct-4 in a highly conserved form and/or nanog in a highly conserved form.
and instructions to use the oocyte, egg, ovary or early embryo, or extract thereof.
Preferably the oocyte, egg, ovary or early embryo cell or cell from which the cell extract is derived, expresses both Oct-4 in a highly conserved form and nanog.
Optionally the kit further comprises one or more differentiated cells to be reprogrammed.
Further optionally the kit may comprise a progenitor medium to effect the further step of re-differentiation of the reprogrammed cell.
In a twelfth aspect of the invention there is provided a method of enhancing cell cloning comprising exposing the cell(s) to be cloned to the isolated cell or cell extract as defined in the sixth aspect of the invention. In this aspect of the invention the cell and/or cell extract is used as form of “pre-dip” to which the cell to be cloned is exposed. The cell and/or cell extract of the invention is capable of aiding the reversion of the cell to be cloned to a more pluripotent state in order to improve the chances and experimental work required to clone the cell.
Examples embodying certain preferred aspects of the invention will now be described with reference to the following figures in which:—
FIG. 1—shows the results of RT-PCR experiments looking for the expression of β-actin, nanog and Oct-4 gene in embryonic stem cells (ES), permeabilised foetal fibroblasts (PFF), and PFFs injected into the GV of either axolotl (PFFA) or Xenopus oocytes (PFFX);
FIG. 2—Axananog expression profile over 40 developmental stages as defined in Bordzilovskaya et al; 1989. Developmental stage series of axolotl embryos. In Developmental Biology of the Axolotl. (ed. J. B. Armstrong and G. M. Malacinski), pp. 210-219. New York: Oxford University Press. EC=Early Cleavage, LC=Late Cleavage;
FIG. 3—shows that the incubation of PFF in extracts from axolotl ovary diminishes the amount of methylated DNA. Differentiated cells were either untreated (Control) or incubated in extracts prepared from axolotl ovary (AxOvEx) for 3 hours (3 h). Cells were stained with antibodies for methylated DNA;
FIG. 4—shows that the incubation of PFF in axolotl ovary extracts (AvOvEx) eliminates H3K9 staining;
FIG. 5—depicts a comparison of skeletons representing evolutionarily conserved primitive and derived adult body plans in fish and amphibians. A. Lungfish skeleton shown from dorsal view. B. Teleost fish shown from a side view. C. Salamander (axolotl) skeleton showed from dorsal view. D. Frog (Xenopus) skeleton showed from dorsal view. Small arrows show ribs. Large arrows point to pelvic bones;
FIG. 6—shows a phylogenetic analysis of class V POU domain transcription factors (Oct-4 like genes). Genes were isolated from the ovaries of the species and compared by parsimony to determine the most closely related sequences. Groups within the same cluster are the most closely related; and
FIG. 7—shows examples of the distribution of germ cell specific RNAs in the cytoplasm of cold blooded vertebrates as indictors of the presence or absence of germ plasm.
FIG. 8—Amino acid alignment of mouse and axolotl Oct-4 using Clustal-W.
FIG. 9—Amino acid alignment of nanog from mouse, rat, human, cow, dog, opossum, chick and axolotl using Clustal-W.
FIG. 10—Axolotl germinal vesicle isolated two days after injection of mammalian cells B—Oocytes injected with human primary fibroblasts were collected at the indicated days and the expression of Actin, Nanog and Oct-4 was analysed by RT-PCR.
FIG. 11—RT-PCR gel showing Nanog and β-actin expression after exposure of differentiated cells to Xenopus, axolotl and/or sturgeon extracts.
FIG. 12—Activation of a reporter gene in which a nanog binding site is present.
FIG. 13—Oct-4 DNA binding domain sequence comparison using Clustal W—highly conserved species.
FIG. 14—Oct-4 DNA binding domain sequence comparison using Clustal W—highly conserved species and non-related species such as Xenopus (XLPOU-60 and XLPOU-91) and Zebrafish (zPou2).
FIG. 15—Table showing sequence identity of highly conserved Oct-4 genes compared to non-conserved Oct-4 equivalents in Xenopus and Zebrafish
FIG. 16—DNA methylation in cells incubated in axolotl oocyte extracts (AOC) was assessed by staining for 5-methylcytosine. Treated cells were sorted by FACS (Fluorescence activated cell sorter) after 1 and 3 hrs of treatment. In addition a group supplemented with apyrase (ATPase inhibitor) was included to show that the process is energy dependent. AP: after permeabilization control.
FIG. 17—Trimethylated Histone H3 Lysine 9 (TriH3K9) in cells incubated in axolotl oocyte extracts was assessed by staining TriH3K9 with a specific antibody. Treated cells were sorted by FACS after 1 and 3 hrs of treatment incubation in extracts. In addition, a group supplemented with apyrase (ATPase inhibitor) was included to show that the process is energy dependent. AP: after permeabilization control.
To demonstrate the ability of oocytes from axolotl to reprogram differentiated mammalian cells, mouse foetal fibroblast cells were injected directly into the GV (germinal vesicle) of Xenopus (PFFX) and axolotl (PFFA) oocytes, using a method similar to that of Byrne et al (2003) Curr Biol 15:13(14) 1206-13 who used only Xenopus.
Cultured mouse foetal fibroblasts were permeabilised by treatment with a mild detergent (digitonin) following the method of Alberio et al (2005) Exp Cell Res. 307(1):131-41. When permeabilised the molecules from the GV can diffuse into the differentiated cell or PFF (permeabilised foetal fibroblast). Approximately 50 to 200 PFF cells were injected per GV, and the injected oocytes were incubated overnight at 21° C. At that time the GV was dissected from the oocyte and those which contained PFF were considered further. RNA was extracted from the GV and reverse transcribed into cDNA and PCR was used to detect the expression of pluripotency genes from the PFF. More particularly PCR was used to determine the expression of genes encoding nanog and Oct-4. β-actin levels were determined as a control.
The above described method has the advantage over known methods in that it concentrates the RNA expressed by the mammalian differentiated cells and leads to a greater sensitivity in detecting mammalian transcripts. Since the aim is to detect mammalian RNA, which is a very tiny fraction of the total RNA, the simple isolation of the GV provides an enormous purification step, and improves sensitivity accordingly.
RT-PCR was performed to detect the expression of the pluripotency marker genes encoding Oct-4 and nanog in the PFF cell. Expression of β-actin was also studied as a control. β-actin is expressed in all cells at all times and serves as a positive control to ensure the efficiency of the assay procedure.
The abbreviations used in
ES—mouse embryonic stem cells (available from Chemicon)
PFF—mouse permeabilised foetal fibroblasts—prepared according to the method of Alberio et al (2005) Exp Cell Res. 307(1):131-41.
PFFA—PFF injected in axolotl oocyte GVs.
PFFX—PFF injected in Xenopus oocyte GVs.
As can be seen from
To conclude, axolotl oocytes induce on contact with permeabilised mammalian differentiated cells robust expression of the pluripotency marker genes encoding Oct-4 and nanog within 18 hours of incubation.
This is in comparison to Xenopus oocytes which although after several days can induce low levels of expression of Oct-4, no expression of nanog can be detected. Thus axolotl oocytes are much more effective at reprogramming the expression of pluripotency marker genes in mammalian differentiated cells than are Xenopus oocytes. Accordingly axolotl oocytes are much more effective at reprogramming differentiated cells to embryonic stem cell-like cells.
In this, and subsequent examples, the expression of a gene is determined by assaying for RNA encoded by the gene.
Xenopus oocyte and egg extracts were prepared according to Hutchison et al., (1988) Development, 103, 553-566. Unfertilised Xenopus eggs were collected from mature females and incubated in dejellying solution (20 mM Tris HCl pH 8.5, 1 mM DTT and 110 mM NaCl) for 5 min. After dejellying, the eggs were rinsed three times in 0.9% NaCl saline and twice in ice-cold extraction buffer (20 mM Hepes, pH 7.5, 100 mM KCl, 5 mM MgCl2, 2 mM β-mercaptoethanol) containing protease inhibitors (3 μg ml-1 leupeptin, 1 μg ml-1 pepstatin and 1 μg ml-1 aprotinin). The eggs were packed into 10-ml centrifuge tubes and excess buffer was removed before centrifugation at 10,000 g for 10 min at 4° C. The cytoplasmic layer was removed and supplemented with 50 μg ml-1 cytochalasin B before centrifugation at 100,000 g for 30 min at 4° C. The cleared cytoplasm was supplemented with 10% glycerol and snap frozen in liquid nitrogen in 100-200 μl aliquots. Oocyte extracts were prepared from mature ovaries by digesting follicle cells for 2 hrs at 25° C. using 1 mg/ml collagenase in OR2 media (82.5 mM NaCl, 2.5 mM KCl, 1 mMCaCl2, 1 mM MgCl2, 1 mM NaHCO3, 5 mM Hepes, pH 7.8). Stage 4-6 oocytes were selected on size, washed in extraction buffer and prepared as for eggs extracts.
For axolotl and Xenopus ovary extracts, the ovaries were washed in ice cold extraction buffer and were lysed by using a Dounce homogeneizer, applying 5-10 strokes on ice. The lysate was centrifuged and cryopreserved as described for Xenopus egg extracts.
Sturgeon (Sterlet sturgeon; Scientific name: Acipenser ruthenus) extract was prepared as follows: for ovary extracts, the ovaries were washed in ice cold extraction buffer (as for frog egg extracts in example 1) and were lysed by using a Dounce homogeneizer, applying 20 strokes on ice. The lysate was centrifuged and cryopreserved as described for Xenopus egg extracts.
Fibroblasts were isolated from a 35-45 day old bovine foetus or from 12.5-13.5 day old mice and cultured for a maximum of five passages in culture medium (CM: DMEM containing 2 mM glutamine, 0.1 mM β-mercaptoethanol, 2 mM non-essential amino acids, 100 IU ml-1 penicillin and 100 μg ml−1 streptomycin supplemented with 10% FBS) at 39° C. for bovine, 37° C. for mouse and human, in 5% CO2. Fibroblasts were isolated from day 13.5 mice (mouse embryonic fibroblasts, MEFs) excluding genital ridges. MEFs were cultured at 37° C. in 5% O2 and CO2 and used at passage 3 or 4.
Cells were grown to 80% confluence and used for the experiments. After trypsinisation, cells were washed in permeabilisation buffer (PB: 20 mM Hepes, pH 7.3, 110 mM potassium acetate, 5 mM sodium acetate, 2 mM magnesium acetate, 1 mM EGTA, 2 mM DTT, and protease inhibitors), and subsequently incubated in 1 ml of 20-30 μg ml−1 digitonin for 1 minute and 15 seconds on ice (Adam et al (1992) Methods Enzymol. 219, 97-110).
The permeabilisation reaction was stopped by adding 10 ml of PB followed by centrifugation at 700 g for 10 minutes at 4° C. Under these conditions, the plasma membrane permeabilisation rate was 95-100%.
Permeabilised cells were added to oocyte/egg/ovary extracts (1,000 cells μl−1 extract) supplemented with an energy regenerating system (ERS: 150 μg ml-1 creatine phosphokinase, 60 mM phosphocreatine Permeabilised MEFs were added to 20 μl of oocyte extract (either Axolotl, Sturgeon or Xenopus) at 5,000 cells/μl and were incubated for 3 hours, 6 hours or overnight at 15° C. Control cells were incubated with 20 μl of PB.
Following incubation, 0.5 mL of PB was added to rinse the cells which were then pelleted at 3,500 G for 5 minutes. The supernatant was removed, and the pellet was frozen at −80° C. until required.
MEF cell pellets were harvested and stored at −80° C. Total RNA was extracted (from ˜100,000 cells) using the RNAeasy system (Qiagen) and DNAse treated (Ambion) before being reverse transcribed using the Superscript III system (Invitrogen). 2 ng of RT reaction was used for RT-PCR.
The primers and conditions used are as follows: B-actin: ttctttgcagctccttcgtt, cttttcacggttggccttag (402 bp; 56° C. annealing, 1 min 10 secs elongation, 32 cycles). Nanog: atgaagtgcaagcggcagaaa, cctggtggagtcacagagtagttc (464 bp; 56° C. annealing, 1 min 10 secs elongation, 35 cycles). Oct-3/4: gtttgccaagctgctgaagc, caccagggtctccgatttgc (238 bp; 56° C. annealing, 1 min 10 secs elongation, 38 cycles). The RediTaq system was used for PCRs (Sigma). Mouse ES cell cDNA was used as a positive control, and no RT as negative controls.
The reaction products were run on a standard 1.2% agarose gel stained with ethidium bromide, and visualized and photographed under UV light (
The left lane shows a 100 bp DNA ladder from Invitrogen, acting as a marker for molecular weight. The top Gel shows the predicted 464 bp DNA band from PCR amplification with nanog primers present in lanes corresponding to cells treated with axolotl or sturgeon extract, but absent in lanes corresponding to cells treated in Xenopus extract, or that were not treated with extract.
The bottom lane shows amplification of mouse β-actin cDNA as a positive control. Note that the predicted 402 bp band is in all lanes as expected, since this gene is not induced by re-programming, it is present in all mouse cells all the time. More cycles of PCR were needed to detect nanog, as expected since this is a regulatory gene and is normally expressed at low levels in cells. β-actin is abundantly expressed, as expected for a structural gene.
In these experiments Oct-4 expression is not activated. This is expected since the Oct-4 promoter is negatively regulated by methylation. Therefore activation requires demethylation of the promoter as a prelude to transcriptional activation, and it is expected that the brief incubation times used in these experiments is not sufficient to demethylate the promoter to completion.
Consistent with this, examples 1 and 5 (injection experiments) show that nanog is relatively easy to activate after injection into the GV of axolotl oocytes. It requires one day for activation. Oct-4 transcription requires about 5 days, presumably reflecting the time needed to demethylate the Oct-4 promoter. Nanog is never activated in cells injected into Xenopus oocytes, even though it does not require prior demethylation.
Another way at looking for the reprogramming of a differentiated cell to a more pluripotent state is to look at the epigenetic profile of a cell. Epigenetic marks are readily apparent in the complex of DNA and proteins (chromatin) of differentiated cells. In many cases epigenetic marks permanently inactivate the transcription of some genes in a cell. Epigenetic marks are often clustered in large regions of DNA that are tightly compacted into a configuration known as heterochromatin. To achieve reprogramming of a differentiated cell to a pluripotent state requires the reversal of some or all of these repressive epigenetic marks thus making most of the DNA accessible to activation. In this regard, pluripotent cells such as embryonic stem cells contain much less heterochromatin and far fewer epigenetic marks than typical differentiated cells. Presumably this reflects the apparent accessibility of all or most of the genes in pluripotent cells for activation, which is a property assumed essential for pluripotency.
Two epigenetic marks are typically associated with inactive genes. The DNA of most cells contains methyl groups (CH3) that are covalently linked to cytosine residues in CpG islands. Methylated DNA (CH3-DNA) is very prominent in heterochromatin, where it can be detected as brightly staining nuclear spots by CH3-DNA specific antibodies in immuno-chemistry experiments. In addition to CH3-DNA, a second epigenetic mark is the addition of CH3 groups to specific residues of histones, the small highly charged nuclear proteins that are bound to DNA to give nuclear DNA a higher order structure referred to as chromatin. Commonly, inactive genes are marked by the presence of CH3 groups added to the lysine residue 9 (K9) of histone H3, H3K9. In this case the methylated histone (CH3-histone) residue is bound to the DNA and inhibits its transcriptional activation. In order to reprogram gene expression of cells to a pluripotent state it will be necessary to diminish the levels of CH3-DNA and CH3-histones within the differentiated cell nucleus. In this regard, embryonic stem cells contain low levels of CH3-DNA and CH3-histone residues.
Axolotl Nanog full-length cDNA was isolated as follows: Axolotl ovary cDNA was used as a template using degenerate primers F (Forward) (named F1): A (G/C) (C/T) CC (A/G/T) GA (T/C) TCT (G/T) C(C/T) AC (A/T/C) AG (T/C) and R (Reverse) (named R4): C (G/T) (T/C) TGGTT (T/C) TG (A/G) AACCA (C/G) GT (T/C) TT (C/A) (for amino acid sequences N-terminal to the Homeodomain and within the Homeodomain, respectively).
PCR (56° C. annealing, 1 minute 10 seconds elongation, 35 cycles) yielded a ˜260 bp fragment.
This fragment was cloned into a plasmid vector and sequenced. Primers were designed for 5′ and 3′ RACE, using RACE-ready Axolotl ovary cDNA.
The Smart RACE kit (Clontech) was used and primers and cDNAs were prepared and RACE reactions carried-out according to kit instructions. RACE primers used were: 5′ RACE (named RACE-R2): TTCGTCTCACCTCCCACCGCTACAT, 3′ RACE (named RACE-F1) CGGCGGATCTCAACCTCACATACAA, along with the corresponding kit primers. 5′ RACE yielded a ˜360 bp fragment and 3′ RACE yielded two fragments of ˜1150 bp and ˜750 bp, reflecting alternative polyadenylation of Axolotl Nanog cDNA. These products were TA cloned and sequenced. A sequence contig of the 3 overlapping products was constructed giving the full Axolotl Nanog cDNA sequence of ˜1.7 kb at its longest. Axolotl nanog amino acid sequence is given in
Permeabilized BJ human adult primary fibroblasts (from ATCC cell bank collection http://www.lgcpromochem-atcc.com/ (CRL-2522)), were injected as described for mouse experiments in example 1, into the germinal vesicle (nucleus) of axolotl oocytes and the injected oocytes were incubated for 5 days at 18° C.
Germinal vesicles were dissected from the oocytes in groups, and those containing human cells were frozen for analysis (
Total RNA was extracted and DNAse I treated, to avoid genomic DNA contamination, using a commercial extraction kit (RNAeasy kit). RNA extracted from each sample was reverse transcribed to generate complimentary DNA (cDNA).
The cDNA was used for amplification by a standard polymerase chain reaction (PCR) using specific primers designed for the following genes: human Nanog (forward 5′ aggcaaacaacccacttctg 3′, and reverse 5′ tcttcggccagttgtttttc 3′), human POU-5F1 (Oct-4 gene; forward 5′ tcccttcgcaagccctcat 3′, reverse 5′ tgacggtgcagggctccggggaggccccat 3′), and human β-Actin (forward 5′ ggacttcgagcaagagatgg 3′, and reverse 5′ agcactgtgttggcgtacag 3′).
As shown in
Hence, adult human cells (differentiated cells) have been reprogrammed to express the Oct-4 and nanog genes after they were injected into the nucleus of axolotl oocytes. Injection into Xenopus oocytes does not result in activation of nanog.
These results are important because they show that both human and mouse cells can be reprogrammed by the cell/cell extract from a cold blooded vertebrate having the properties of the invention (e.g. primitive vertebrate body plan) and that adult cells can be reprogrammed. Differentiated adult cells are more difficult to reprogram than foetal cells, which are still progressing in their development and may not have had permanent epigenetic marks imposed on the chromatin.
Incubating the injected oocytes at 18 degrees, rather than room temperature presents advantages in the enhanced survivability of the injected oocytes, which can be cultured for at least 5 days which allows sufficient time to trigger activation of Oct-4. Also, as transcription from the mammalian genome is temperature dependent (Alberio et al, 2005) the repression of transcription at this temperature might further aid reprogramming.
To show that nanog is present it is possible to show that the nanog can activate reporter genes that contain a nanog binding site, such as the promoter of GATA-4. In
In this experiment empty DNA was compared with human nanog and two clones driving expression of Axnanog.
NIH3T3 cells were seeded into 24 well plates and transfected with 0.25 ug/well GATA-4 reporter, 0.05 ug/well pTK-RL (Promega) and either empty vector (cDNA), human Nanog, or Axolotl nanog untagged (CMV) or RFP tagged (mR) using Lipofectamine 2000 reagent (Invitrogen). 24 hours Post-transfection cells were harvested and processed for Dual luciferase assay (Promega). RLU (relative luciferase units) were ratioed to the empty vector control. Bars show standard deviation; n=3
The expression profile of Axnanog was examined and compared to compare the profile of the mouse nanog gene. It was found that Axnanog is expressed exactly when it would be expected to be expressed if it were to play a role in pluripotency during axolotl development.
In mouse embryos the nanog gene is expressed very briefly during early development tin the cells of the inner cell mass and early blastocyst. It is known to play an essential role in the maintenance of pluripotency during this period. To test if Axnanog is expressed during an equivalent period, we analysed its expression in early embryos. A low level of maternal Axnanog RNA is detectable during early and late cleavage stages (EC; LC) then robust expression commences at stage 9, marking the mid-blastula transition, when transcription from the zygotic genome of axolotl embryos commences. Expression peaks in early gastrula, (stage 10), and declines in late gastrula (stage 12). Expression is undetectable in later stages. Thus, Axnanog is expressed during a window of development that coincides with the presence of pluripotent cells, and expression is extinguished after gastrula stages, when all cells are thought to have undergone commitment to a somatic cell lineage, and would not be expected to be pluripotent.
RNA was extracted from 5 axolotl embryos at each of the indicated stages in
The RNA was reverse transcribed using Superscript (Invitrogen). 0.5 embryo equivalents of cDNA from each stage was used in a PCR with primers for Axnanog (F1: GTTCCAGAACCGAAGGATGA; R1: CGAAGGGTACTGCAGAGGAG 58 C, 45 sec, 72 deg. 1 min) or Axolotl ornithine decarboxylase (ODC; F1: TGCGTTGGTTTAAAGCTCTC; R1: ACATGGAAGCTCACACCAAT 56 C 45 sec; 72 C 1 min), a constitutively expressed gene used a positive control for cDNA integrity. PCR was for 35 cycles (Axnanog) or 30 cycles (ODC).
The reaction products were separated on a 1.2% agarose gel containing ethidium bromide, then photographed under UV light (
The global DNA demethylation was confirmed by flow cytometry using the protocol described previously (Habib et al., (1999). Exp. Cell Res. 249, 46-53.) with slightly modifications.
Cells in suspension were submitted to successive low-speed (300 g) pelleting and gentle resuspension steps in washed twice with phosphate buffered saline (PBS) supplemented with 0.1% tween 20 and 1% bovine serum albumin (BSA) and then were fixed with 9 vol of methanol/PBS (88% methanol/12% PBS vol/vol) refrigerated at −20° C. for 20 minutes. After two washes with PBST-BSA at room temperature cells were treated successively with 2 N HCl at 37° C. for 30 minutes, then with Tris HCL buffer (pH 8.8) for 5 min. Then cells were treated for 1 hour at 37° C. with a blocking solution made of PBS-T supplemented with 5% BSA, following the incubation with anti-5-MeC antibody (where) at 4° C. over night.
Cells were then successively rinsed three times with PBS-T and incubated for 1 hour at room temperature with rabbit anti-mouse immunoglobulin conjugated to fluorescein isothiocyanate (Dako, Trappes, France) diluted 1 in 200 in PBST-BSA. Finally samples were washed three times with PBS and were stained with propidium iodide (PI) (50 mg/ml in PBS) for 30 min before flow cytometry. Analyses were performed by Epics XL flow cytometer (Beckman Coulter).
Similar protocols were used for detecting the changes of H3K9 and HP1 alpha by flow cytometry. Briefly, cells were washed twice with pH 7.4 PBS supplemented with 1% BSA and 0.1% Tween 20 (PBST-BSA) and then were fixed with 9 vol of methanol/PBS (88% methanol/12% PBS vol/vol) refrigerated at −20° C. for 20 minutes.
Then cells were treated for 1 hour at 37° C. with a blocking solution made of PBS-T supplemented with 5% BSA, following the incubation with anti-Tri methylated H3K9 or anti-HP1 alpha antibody (where) at 4° C. over night. Cells were then successively rinsed three times with PBS-T and incubated for 1 hour at room temperature with Dunkey anti rabbit (1:100, Juckson USA) or goat anti-mouse immunoglobulins conjugated to fluorescein isothiocyanate (Dako, Trappes, France) diluted 1 in 200 in PBST-BSA respectively.
Finally samples were washed three times with PBS and were stained with propidium iodide (PI) (50 mg/ml in PBS) for 30 min before flow cytometry.
Analyses were performed by Epics XL flow cytometer (Beckman Coulter).
The results of the flow cytometry are given in
The cells were sorted based on the fluorescence staining with the CH3-DNa antibody, and the histone H3K9 antibody, and then examined for what percentage of the cells have the full control level of staining, and what percentage show diminished fluorescence over time.
As the figures show, the overall level of fluorescence in the cell, in both experiments is reduced. This confirms the earlier results and demonstrates that loss of methylated DNA and Histone H3K9 is being achieved.
The cells and cell extracts of the invention may be used in enhancing cloning procedures such as sheep cloning by incubating the cells with Axolotl oocyte extracts prior to nuclear transfer (NT).
Sheep fibroblasts were permeabilized as described for bovine cells by Alberio et al., (2005). The cells were incubated in axolotl oocyte extracts at 18° C. for 3 hrs and then used as nuclear donors for NT. Permeabilized cells are normally easily recognised under a microscope with a swollen and round shape and were therefore chosen for NT. The nuclear transfer procedure was carried out in the same manner as described by Lee et al., (2006) Biol Reprod. 74:691-8.
After 7 days in culture development to blastocyst was assessed under a microscope. Five cloned embryos developed to blastocyst after 7 days, indicating that cells incubated in axolotl extracts are viable donors for NT.
This experiment has shown that exposure of mammalian somatic cells to axolotl oocyte extracts is not detrimental for preimplantation development of mammalian cloned embryos.
It is expected that these embryos will show an improvement in the development to term of cloned embryos made with cells exposed to extracts of the invention. Gestation and development of the embryos is ongoing.
The cells and cell extracts of the inventions can be provided in the form of a kit for use in the method of the invention. These kits preferably contain the cell/cell extract reagent, and at least one of the following:
Instructions for use; progenitor medium for re-differentiation of the reprogrammed cells; disposable equipment for conducting the re-programming e.g. multi-well plates, dispensers such as pre-loaded pipettes; differentiated cells to be reprogrammed and permeabilization Buffer.
The kits may be customised according to the re-differentiated cell type is required in that the progenitor medium and the instructions may vary according to the cell type and end use.
A further aspect of the invention provides a pharmaceutical formulation comprising a compound according to the first aspect of the invention in admixture with a pharmaceutically or veterinarily acceptable adjuvant, diluent or carrier.
Preferably, the formulation is a unit dosage containing a daily dose or unit, daily sub-dose or an appropriate fraction thereof, of the active ingredient.
The compounds of the invention will normally be administered orally or by any parenteral route, in the form of a pharmaceutical formulation comprising the active ingredient, optionally in the form of a non-toxic organic, or inorganic, acid, or base, addition salt, in a pharmaceutically acceptable dosage form. Depending upon the disorder and patient to be treated, as well as the route of administration, the compositions may be administered at varying doses.
In human therapy, the compounds of the invention can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
For example, the compounds of the invention can be administered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed- or controlled-release applications. The compounds of invention may also be administered via intracavernosal injection.
Such tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxy-propylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the compounds of the invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
The compounds of the invention can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intrasternally, intracranially, intra-muscularly or subcutaneously, or they may be administered by infusion techniques. They are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
For oral and parenteral administration to human patients, the daily dosage level of the compounds of the invention will usually be from 1 mg/kg to 30 mg/kg. Thus, for example, the tablets or capsules of the compound of the invention may contain a dose of active compound for administration singly or two or more at a time, as appropriate. The physician in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.
The compounds of the invention can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray or nebuliser with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A3 or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227EA3), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray or nebuliser may contain a solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
Aerosol or dry powder formulations are preferably arranged so that each metered dose or “puff” delivers an appropriate dose of a compound of the invention for delivery to the patient. It will be appreciated that the overall daily dose with an aerosol will vary from patient to patient, and may be administered in a single dose or, more usually, in divided doses throughout the day.
Alternatively, the compounds of the invention can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder. The compounds of the invention may also be transdermally administered, for example, by the use of a skin patch. They may also be administered by the ocular route, particularly for treating diseases of the eye.
For ophthalmic use, the compounds of the invention can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.
For application topically to the skin, the compounds of the invention can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouth-washes comprising the active ingredient in a suitable liquid carrier.
Generally, in humans, oral or topical administration of the compounds of the invention is the preferred route, being the most convenient. In circumstances where the recipient suffers from a swallowing disorder or from impairment of drug absorption after oral administration, the drug may be administered parenterally, e.g. sublingually or buccally.
For veterinary use, a compound of the invention is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will determine the dosing regimen and route of administration which will be most appropriate for a particular animal.
| Number | Date | Country | Kind |
|---|---|---|---|
| 0515006.5 | Jul 2005 | GB | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/GB2006/002754 | 7/21/2006 | WO | 00 | 7/16/2008 |
